SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lincoln Pharmaceuticals informs about outcome of board meeting

09 Aug 2022 Evaluate
Lincoln Pharmaceuticals has informed that the Board of Directors of the Company at its meeting held today, on Tuesday, August 9, 2022, have considered/ approved/ recommended, the followings: The un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2022 along with the limited review report from auditors thereon. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of un-audited consolidated financial results for the quarter ended on June 30, 2022. The un-audited financial results (standalone and consolidated) will be available at Company's website at www.lincolnpharma.com. Further, it enclosed financial highlights for the aforesaid quarter; The appointment of Anand A. Patel (DIN: 00103316) as an additional and whole time director in the category of executive director of the Company with effect from August 9, 2022, subject to the approval of the Members at the ensuing AGM, in terms of provisions of Section 196, 197 and other applicable provisions of the Companies Act, 2013 and Rule framed thereunder and as per relevant regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; The appointment of Samir M. Shah & Associates, Chartered Accountants (Firm Reg. No. 122377W), Ahmedabad as the statutory auditors of the Company for a period of five years from the conclusion of 28th Annual General Meeting (AGM) till the conclusion of the 33rd AGM, in place of retiring auditors and recommended for final approval of the members at the ensuing AGM; and approved the resignation tendered by Arvind G. Patel, Non-Executive Non-Independent Director of the Company from the position of Director of the Company to be made effective from August 9, 2022 after the closure of the business hours.

The above information is a part of company’s filings submitted to BSE.

Lincoln Pharma Share Price

679.45 38.20 (5.96%)
05-May-2026 15:12 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1821.25
Dr. Reddys Lab 1269.70
Cipla 1332.70
Zydus Lifesciences 908.80
Lupin 2345.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×